Design of nanostructured lipid carriers and solid lipid nanoparticles for enhanced cellular uptake

Veider, Florina; Akkuş‐Dağdeviren, Zeynep Burcu; Knoll, Patrick; Bernkop‐Schnürch, Andreas

doi:10.1016/j.ijpharm.2022.122014

Cited by 28 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in case of control groups, no statistically significant amount of monophosphate was released throughout the entire experiment (data not shown). These results confirm that PMB–PP NPs reach membrane-bound IAP at the intestinal brush border membrane leading to phosphate cleavage . Results are in good agreement with a previous study carried out by Nazir et al using chitosan and chondroitin sulfate to form nanoparticles that were additionally phosphorylated.…”

Section: Resultssupporting

confidence: 92%

“…The cytotoxic potential of PMB–PP NPs was investigated on Caco-2 cells using a resazurin assay. , The toxicity profile of PMB–PP NPs was investigated in concentrations ranging from 0.001% to 0.01% m/v, as shown in Figure .…”

Section: Resultsmentioning

confidence: 99%

“…Owing to the highly charged nature of polyphosphates at physiological pH they have been used to form polymeric NPs with oppositely charged polycations through ionic cross-linking resulting in particles with a small size and low polydispersity . Moreover, PP being regarded as safe auxiliary agents have been used in food industry as well and their mucus-permeating properties have already been reported. , …”

Section: Resultsmentioning

confidence: 99%

“…16 Moreover, PP being regarded as safe auxiliary agents have been used in food industry as well 26 and their mucus-permeating properties have already been reported. 27,28 The ionic strength of the polycation plays also an important role in the formation of such particles. Since PMB exhibits pK a values of 9.07, 9.54, 9.84, 10.02, and 10.24 and an isoelectric point of 10.74, it is a highly positively charged peptide at pH 7.4.…”

Section: Preparation and Characterization Of Pmb−ppmentioning

confidence: 99%

See 3 more Smart Citations

Peptide Antibiotic–Polyphosphate Nanoparticles: A Promising Strategy to Overcome the Enzymatic and Mucus Barrier of the Intestine

et al. 2023

Self Cite

View full text Add to dashboard Cite

The aim of this study was to develop peptide antibiotic–polyphosphate nanoparticles that are able to overcome the enzymatic and mucus barriers providing a targeted drug release directly on the intestinal epithelium. Polymyxin B–polyphosphate nanoparticles (PMB–PP NPs) were formed via ionic gelation between the cationic peptide and the anionic polyphosphate (PP). The resulting NPs were characterized by particle size, polydispersity index (PDI), zeta potential, and cytotoxicity on Caco-2 cells. The protective effect of these NPs for incorporated PMB was evaluated via enzymatic degradation studies with lipase. Moreover, mucus diffusion of NPs was investigated with porcine intestinal mucus. Isolated intestinal alkaline phosphatase (IAP) was employed to trigger the degradation of NPs and consequent drug release. PMB–PP NPs exhibited an average size of 197.13 ± 14.13 nm, a PDI of 0.36, a zeta potential of −11.1 ± 3.4 mV and a concentration and time-dependent toxicity. They provided entire protection toward enzymatic degradation and exhibited significantly (p < 0.05) higher mucus permeating properties than PMB. When incubated with isolated IAP for 4 h, monophosphate and PMB were constantly released from PMB–PP NPs and zeta potential raised up to −1.9 ± 0.61 mV. According to these findings, PMB–PP NPs are promising delivery systems to protect cationic peptide antibiotics against enzymatic degradation, to overcome the mucus barrier and to provide drug release directly at the epithelium.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Preparation and Characterization Of Pmb−ppmentioning

confidence: 99%

See 2 more Smart Citations

Peptide Antibiotic–Polyphosphate Nanoparticles: A Promising Strategy to Overcome the Enzymatic and Mucus Barrier of the Intestine

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anionic polyphosphate coatings of originally cationic NPs enhance mucus permeation, nevertheless guaranteeing facilitated cellular uptake since these coatings are cleaved on the cellular membrane by phosphatase. [ 116 ] As polyphosphates, Graham's salt, tripolyphosphate, and phytic acid are used. [ 79 ] The layer‐by‐layer coating method with tripolyphosphate was applied in a recent study exemplifying possibilities of a tunable surface charge.…”

Section: Applications For Charge‐reversible Nanoparticlesmentioning

confidence: 99%

Charge‐Reversible Nanoparticles: Advanced Delivery Systems for Therapy and Diagnosis

Veider,

Sanchez Armengol,

Bernkop‐Schnürch

2023

Small

Self Cite

View full text Add to dashboard Cite

The past two decades have witnessed a rapid progress in the development of surface charge‐reversible nanoparticles (NPs) for drug delivery and diagnosis. These NPs are able to elegantly address the polycation dilemma. Converting their surface charge from negative/neutral to positive at the target site, they can substantially improve delivery of drugs and diagnostic agents. By specific stimuli like a shift in pH and redox potential, enzymes, or exogenous stimuli such as light or heat, charge reversal of NP surface can be achieved at the target site. The activated positive surface charge enhances the adhesion of NPs to target cells and facilitates cellular uptake, endosomal escape, and mitochondrial targeting. Because of these properties, the efficacy of incorporated drugs as well as the sensitivity of diagnostic agents can be essentially enhanced. Furthermore, charge‐reversible NPs are shown to overcome the biofilm formed by pathogenic bacteria and to shuttle antibiotics directly to the cell membrane of these microorganisms. In this review, the up‐to‐date design of charge‐reversible NPs and their emerging applications in drug delivery and diagnosis are highlighted.

show abstract

Ephedra intermedia Schrenk & C. A. Mey Methanol Extract: Nanoencapsulation by Mini‐Emulsion Polymerization and its Release Trend under Simulated Conditions of the Human Body

Mahdavi,

Ebrahimi,

Farzi

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

In this research, the extract of Ephedra intermedia Schrenk &C.A.Mey was encapsulated using the mini‐emulsion polymerization method based on methyl methacrylate polymers with a nanometer size. The encapsulated extract was characterized using different analytical techniques. Furthermore, the loading efficiency and release of the plant extract were examined. FT‐IT spectroscopy confirmed the formation of an expectational product. The TEM and SEM imaging showed a spherical morphology for the prepared encapsulated extract. The average size of poly‐methyl‐methacrylate nanoparticles containing Ephedra extract was found to be approximately 47 nm. The extract loading efficiency and encapsulation efficiency test demonstrated a dose‐depending behavior on E. intermedia extract for both analyses, which is highly advantageous for traversing biological barriers. The release assay shows a controlled release for the extract at phosphate buffer solution (PBS). A 38% release was calculated after 36 hours. The results obtained from the present study reveal that encapsulating the plant extract is a suitable alternative to control and increase their medicinal properties.

show abstract

Design of nanostructured lipid carriers and solid lipid nanoparticles for enhanced cellular uptake

Cited by 28 publications

References 45 publications

Peptide Antibiotic–Polyphosphate Nanoparticles: A Promising Strategy to Overcome the Enzymatic and Mucus Barrier of the Intestine

Peptide Antibiotic–Polyphosphate Nanoparticles: A Promising Strategy to Overcome the Enzymatic and Mucus Barrier of the Intestine

Charge‐Reversible Nanoparticles: Advanced Delivery Systems for Therapy and Diagnosis

Ephedra intermedia Schrenk & C. A. Mey Methanol Extract: Nanoencapsulation by Mini‐Emulsion Polymerization and its Release Trend under Simulated Conditions of the Human Body

Contact Info

Product

Resources

About